Targets › LILRA6
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
May act as receptor for class I MHC antigens. (UniProt, Q6PI73)
Open in Phaseline: the race on LILRA6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Anti-LILRA6 CAR-T cells anti-LILRA6 chimeric antigen receptor T cell therapy | LILRA6 | Phase 1 | Refractory Acute Myeloid Leukemia | Oct 2027 |
Refractory Acute Myeloid Leukemia (1)
other (1)
Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.